Aventis Pharmaceuticals Inc.

Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

Aventis Pharma Limited

Rhone Poulenc Rorer

Aventis Pharmaceuticals Products Inc.

Daniel Gerard McGarry

Stefanie Keil

Wolfgang Wendler

Jochen Goerlitzer

Karen Chandross

Jean Merrill

Francis A Volz

Stevan Wakefield Djuric

John R Regan

Robert D Groneberg

Gregory Bernard Poli

Paul Joseph Cox

David John Aldous

Kevin Joseph Moriarty

Anne Minnich

Rose Mappilakunnel Mathew

Michael F Kelley

Christopher Hulme

Fu-Chih Huang

Christopher J Burns

Gregory H Merriman

Richard F Labaudiniere

Alexandre Gross

Peter Charles Astles

William P Dankulich

Gerard M McGeehan

Patrick Bernardelli

Patrick Shum

David Rampe

Jeffrey Stephen Sabol

Mark A Bobko

Liang Ma

Litao Zhang

Garth E Ringheim

Zaid Jayyosi

Shelley Bower

Alfred P Spada

Timothy Francis Gallagher

Heinz W Pauls

Baptiste Ronan

Scott I Klein

Robert L Morris

Maike Glien

Kevin Richard Guertin

Corinne Terrier

Thomas Caulfield

Yong Gong

Thomas J Caulfield

Mark Bobko

The present invention is directed to 1,3,4-oxadiazalones, compounds of formula I and their pharmaceutically acceptable salts stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein. The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization.

1, 3, 4-oxadiazol-2-ones as PPAR delta modulators and their use thereof

The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R, R, R, R, R, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.

Heterocyclic compounds as P2X7 ion channel blockers

The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing peroxisome proliferator activator receptor (PPAR) delta agonist activity comprising compounds of formula I, in which the R1-R7 substituents as well as the U, V, W, X Y and z radicals are as defined herein, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuro-inflammatory processes and/or other peripheral neuropathies.

Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists

The present invention is directed to 1,3,4-oxadiazalones, i.e., the compounds of formula I and their pharmaceutically acceptable salts, stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein.  The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization such as multiple scleroses.

1, 3, 4-oxadiazol-2-ones as peroxisome-proliferator activated receptor delta modulators and their use in the treatment of neurological and metabolic disease

The present invention is directed to 1,3,4-oxadiazolones, compounds of formula I and their pharmaceutically acceptable salts stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein.  The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization.

1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof

The use of diaryl acid derivatives of formula (I)or pharmaceutically acceptable salts, N-oxides, hydrates or solvates thereof, wherein the variables shown are defined in the disclosure, and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.

Therapeutic uses of di-aryl acid derivatives

This invention is directed to physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and pharmaceutically acceptable salts of the compounds of formula (I) and N-oxides thereof, Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmnaceutical compositions comprising compoundS of formula (I), their phatmaceUtical use and methods for their preparation.

Substituted azabicyclic compounds

The use of triaryl acid derivatives of formula (I)and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.

Therapeutic uses of tri-aryl acid derivatives

This invention is directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans that inhibit Factor Xa, pharmaceutical compositions comprising these compounds and their use for inhibiting Factor Xa or treating pathological conditions in a patient that may be ameliorated by administration of such compounds. This invention is also is also directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans which directly inhibit both Factor Xa and Factor IIa (thrombin), to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of simultaneously directly inhibiting both Factor Xa and Factor IIa (thrombin).

Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans

This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds

This invention relates to compounds of formula

Substituted N-&lsqb;(aminoiminomethyl or aminomethyl)phenyl&rsqb;propyl amides

This invention is directed to certain physiologically active compounds of formula (I)

Growing community of inventors

Branchburg, NJ, United States of America

Daniel Gerard McGarry